Main public logs

Combined display of all available logs of wikidoc. You can narrow down the view by selecting a log type, the username (case-sensitive), or the affected page (also case-sensitive).

21:19, 9 March 2025 Omid Afkhami-Ardakani talk contribs created page Ga-68-DOTATOC (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Gallium-68 DOTATOC |aOrAn=a |drugClass=radiopharmaceutical diagnostic agent |indicationType=procedure |indication=positron emission tomography (PET) imaging for the localization of somatostatin receptor-positive neuroendocrine tumors (NETs) in adult and pediatric patients. |adverseReactions=Nausea, Vomiting, Flushing, Injection site pain |blackBoxWarningTitle='''TITLE</...")
21:03, 9 March 2025 Omid Afkhami-Ardakani talk contribs created page Lefamulin (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Lefamulin |aOrAn=a |drugClass=Pleuromutilin Antibiotic |indicationType=treatment |indication=adults with community-acquired bacterial pneumonia (CABP) caused by susceptible microorganisms. |adverseReactions=injection: administration site reactions, hepatic enzyme elevation, nausea, hypokalemia, insomnia, headache. Oral: diarrhea, nausea, vomiting, hepatic enzyme elevation. |blackBoxWarningTit...")
20:47, 9 March 2025 Omid Afkhami-Ardakani talk contribs created page Upadacitinib (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Upadacitinib |aOrAn=a |drugClass=Janus Kinase (JAK) Inhibitor |indicationType=treatment |indication=Moderate to severe active rheumatoid arthritis, Active psoriatic arthritis, Moderate to severe atopic dermatitis, Moderate to severe ulcerative colitis, Moderate to severe active Crohn's disease, Active ankylosing spondylitis, and Active non-radiographic axial spondyloarthritis. |hasBlackBoxWarning=Y...")
20:30, 9 March 2025 Omid Afkhami-Ardakani talk contribs created page Fedratinib (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Fedratinib |aOrAn=a |drugClass=Janus Kinase 2 (JAK2) Inhibitor |indicationType=treatment |indication=adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF). |hasBlackBoxWarning=Yes |adverseReactions=Diarrhea, Nausea, Vomiting, Fatigue, Anemia, Thrombocytopenia, Elevated liver enzymes (ALT/AST), and Elevated...")
03:46, 9 March 2025 Edzelco talk contribs created page File:Cipaglucosidase alfa-atga 25 count.png (RINCIPAL DISPLAY PANEL - NDC: 71904-200-03 - 105 MG/VIAL 25 COUNT MULTIPACK LABEL)
03:46, 9 March 2025 Edzelco talk contribs uploaded File:Cipaglucosidase alfa-atga 25 count.png (RINCIPAL DISPLAY PANEL - NDC: 71904-200-03 - 105 MG/VIAL 25 COUNT MULTIPACK LABEL)
03:46, 9 March 2025 Edzelco talk contribs created page File:Cipaglucosidase alfa-atga 10 count.png (PRINCIPAL DISPLAY PANEL - NDC: 71904-200-02 - 105 MG/VIAL 10 COUNT MULTIPACK LABEL)
03:46, 9 March 2025 Edzelco talk contribs uploaded File:Cipaglucosidase alfa-atga 10 count.png (PRINCIPAL DISPLAY PANEL - NDC: 71904-200-02 - 105 MG/VIAL 10 COUNT MULTIPACK LABEL)
03:45, 9 March 2025 Edzelco talk contribs created page File:Cipaglucosidase alfa-atga carton label.png (PRINCIPAL DISPLAY PANEL - NDC: 71904-200-01 - 105 MG/VIAL 1 COUNT CARTON LABEL)
03:45, 9 March 2025 Edzelco talk contribs uploaded File:Cipaglucosidase alfa-atga carton label.png (PRINCIPAL DISPLAY PANEL - NDC: 71904-200-01 - 105 MG/VIAL 1 COUNT CARTON LABEL)
03:44, 9 March 2025 Edzelco talk contribs created page File:Cipaglucosidase alfa-atga.png (PRINCIPAL DISPLAY PANEL - NDC: 71904-200-01 - 105 MG/VIAL 1 COUNT VIAL LABEL)
03:44, 9 March 2025 Edzelco talk contribs uploaded File:Cipaglucosidase alfa-atga.png (PRINCIPAL DISPLAY PANEL - NDC: 71904-200-01 - 105 MG/VIAL 1 COUNT VIAL LABEL)
17:08, 7 March 2025 User account Meghana Kodali talk contribs was created by Alberto Castro Molina talk contribs
02:47, 13 February 2025 Parth Vikram Singh talk contribs created page Inavolisib (Created page with "{{DrugProjectFormSinglePage |authorTag=Parth Vikram Singh |genericName=Inavolisib |aOrAn=a |drugClass=phosphoinositide 3-kinase inhibitors |indicationType=treatment |indication=Inavolisib is a phosphoinositide 3-kinase inhibitor that is FDA approved for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer Breast cancer,...")
10:56, 12 February 2025 Nehal Eid talk contribs created page Zenocutuzumab-zbco (Created page with "{{DrugProjectFormSinglePage |aOrAn=a |drugClass=HER2-and HER3-directed antibody |indicationType=treatment |indication=It is a bispecific HER2-and HER3-directed antibody indicated for the treatment of: • Adults with advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy.* • Adults with advanced, unresectable or metastatic pancreatic adenocarc...")
10:20, 12 February 2025 Nehal Eid talk contribs created page Cosibelimab-ipdl (Created page with "{{DrugProjectFormSinglePage |authorTag=Nehal Eid |aOrAn=a |drugClass=programmed death ligand-1 (PD-L1) blocking antibody |indicationType=treatment |indication=It is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation. |adverseReactions=The most common adverse reactions (≥10%) were fatigue, musculoskeletal pain, rash, diarrhea,...")
09:56, 12 February 2025 Nehal Eid talk contribs created page Ensartinib (Created page with "{{DrugProjectFormSinglePage |authorTag=Nehal Eid |aOrAn=a |drugClass=Kinase inhibitor |indicationType=treatment |indication=It is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK-inhibitor. |adverseReactions=Most common adverse reactions (incidence≥20%) were rash, musculoskeletal pain, constipation, pruritus, cough, nause...")
22:57, 8 February 2025 Omid Afkhami-Ardakani talk contribs created page Entrectinib (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Entrectinib |aOrAn=a |drugClass=Tyrosine Kinase Inhibitor |indicationType=treatment |indication=Adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. And also adult and pediatric patients 12 years of age and older with solid tumors. |adverseReactions=Fatigue, Constipation, Dysgeusia (altered taste), Edema, Dizziness, Diarrhea, Nausea, Dysesthesia (abnorma...")
20:37, 6 February 2025 Mohammad Waqas Danish talk contribs created page File:Renal Impairment dose.png
20:37, 6 February 2025 Mohammad Waqas Danish talk contribs uploaded File:Renal Impairment dose.png
20:35, 6 February 2025 Mohammad Waqas Danish talk contribs created page File:Enmetazobactam Structure.png
20:35, 6 February 2025 Mohammad Waqas Danish talk contribs uploaded File:Enmetazobactam Structure.png
20:17, 6 February 2025 Mohammad Waqas Danish talk contribs created page File:Cefepime structure.png
20:17, 6 February 2025 Mohammad Waqas Danish talk contribs uploaded File:Cefepime structure.png
19:03, 31 January 2025 Nehal Eid talk contribs created page Olezarsen (Created page with "{{DrugProjectFormSinglePage |authorTag=Nehal Eid |aOrAn=an |drugClass=Oligonucleotide |indicationType=treatment |indication=It is indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). |adverseReactions=1-Injection site reactions 2-Decreased platelet count 3-Arthralgia |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:''...")
20:33, 30 January 2025 Mohammad Waqas Danish talk contribs created page Cefepime, enmetazobactam (Created page with "{{DrugProjectFormSinglePage |authorTag=Mohammad Waqas Danish, MBBS |genericName=Cefepime and Enmetazobactam |aOrAn=an |drugClass=fourth generation cephalosporin with an extended spectrum Beta-Lactamase Inhibitor |indicationType=treatment |indication=complicated urinary tract infections, including p.yelonephritis |adverseReactions=increase in transaminases, increased bilirubin, headache, and phlebitis/infusion site reactions. |blackBoxWarningTitle='''<span style="color:#...")
17:10, 30 January 2025 Nehal Eid talk contribs created page Concizumab (Created page with "{{DrugProjectFormSinglePage |authorTag=Nehal Eid |indicationType=treatment |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Concizumab in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-Supported...")
16:06, 29 January 2025 Amir Ghabousian talk contribs created page Zelsuvmi (Created page with "{{DrugProjectFormSinglePage |authorTag=Amir Ghabousian |genericName=Berdazimer |indicationType=treatment |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |fdaLIADAdult=== Indications == '''Molluscum contagiosum''' == Dosing == * Zelsuvmi comes in a carton with Tube A (berdazimer gel), Tube B (hydrogel), and a dosing guide. * Dispense an equal amount of gel ('...")
17:13, 28 January 2025 User account Mohammad Waqas Danish talk contribs was created by Alberto Castro Molina talk contribs
17:01, 28 January 2025 User account Parth Vikram Singh talk contribs was created by Alberto Castro Molina talk contribs
21:15, 27 January 2025 User account Nehal Eid talk contribs was created by Alberto Castro Molina talk contribs
19:56, 27 January 2025 User account Amir Ghabousian talk contribs was created by Alberto Castro Molina talk contribs
09:19, 25 January 2025 Ali Othman talk contribs created page User:Ali Othman (Created page with "'''Ali Othman, MD''' email: alimoameed18@gmail.com") Tag: Visual edit
09:07, 25 January 2025 Ali Othman talk contribs created page PrabotulinumtoxinA-xvfs (Created page with "{{DrugProjectFormSinglePage |genericName=prabotulinumtoxinA-xvfs |aOrAn=a |drugClass=HUMAN PRESCRIPTION DRUG LABEL |indicationType=treatment |indication=JEUVEAU is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients |hasBlackBoxWarning=Yes |adverseReactions=The following serious adve...")
08:23, 23 January 2025 Ali Othman talk contribs created page File:9BE06259-054C-4FF2-877B-F5D48B7866FA.jpg
08:23, 23 January 2025 Ali Othman talk contribs uploaded File:9BE06259-054C-4FF2-877B-F5D48B7866FA.jpg
10:11, 21 January 2025 Ali Othman talk contribs created page Template:AO,MD (Created page with "Ali Othman, M.D [alimoameed18@gmail.com]")
15:08, 16 January 2025 User account Ali Othman talk contribs was created by Alberto Castro Molina talk contribs
13:14, 21 December 2024 Omid Afkhami-Ardakani talk contribs created page Pitolisant (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami Ardakani |genericName=Pitolisant |aOrAn=a |drugClass=Histamine-3 (H3) Receptor Antagonist/Inverse Agonist |indicationType=treatment |indication=Excessive daytime sleepiness (EDS) or cataplexy in adult patients and in pediatric patients aged 6 years and older with narcolepsy. |adverseReactions=Insomnia, Nausea, Anxiety, Headache, Irritability, Dizziness, Depression, Tremor, Sleep disorders, Fatigue, Vomiting, Vertigo, Dy...")
18:33, 8 December 2024 Omid Afkhami-Ardakani talk contribs created page Pretomanid (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami Ardakani |genericName=Pretomanid |aOrAn=a |drugClass=Nitroimidazooxazine Antimycobacterial |indicationType=treatment |indication=Pulmonary extensively drug-resistant (XDR) tuberculosis (TB), Treatment-intolerant or nonresponsive multidrug-resistant (MDR) pulmonary TB |adverseReactions=Peripheral neuropathy, Acne, Anemia, Nausea, Vomiting, Headache, Increased transaminases, Dyspepsia, Rash, and Decreased appetite. |fdaLI...")
17:55, 8 December 2024 Omid Afkhami-Ardakani talk contribs created page Pexidartinib (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami Ardakani |genericName=Pexidartinib |aOrAn=a |drugClass=Tyrosine Kinase Inhibitor |indicationType=treatment |indication=Tenosynovial Giant Cell Tumor (TGCT). |hasBlackBoxWarning=Yes |adverseReactions=Increased liver enzymes (e.g., AST, ALT), Hair color changes, Increased cholesterol levels, Decreased white blood cell counts, Fatigue, Edema, Rash, and Dysgeusia (altered taste). Decreased phosphate levels |blackBoxWarning...")
01:24, 3 December 2024 Medhat talk contribs created page File:1111111111111111111111111111111111111111111111111111111111111111111.jpg
01:24, 3 December 2024 Medhat talk contribs uploaded File:1111111111111111111111111111111111111111111111111111111111111111111.jpg
01:20, 3 December 2024 Medhat talk contribs created page File:A3s4.png (test)
01:20, 3 December 2024 Medhat talk contribs uploaded File:A3s4.png (test)
01:17, 3 December 2024 Medhat talk contribs created page User talk:Medhat (test)
17:03, 24 November 2024 Omid Afkhami-Ardakani talk contribs created page Nubeqa (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami Ardakani |genericName=Darolutamide |aOrAn=a |drugClass=Nonsteroidal Antiandrogen (NSAA) |indicationType=treatment |indication=Non-metastatic Castration-Resistant Prostate Cancer (nmCRPC) in adult men. It can also be used for treatment of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) in combination with docetaxel in adult men. |adverseReactions=Fatigue, Pain in extremities, Rash, Decreased neutrophil count, and I...")
20:23, 19 November 2024 SemRikken talk contribs created page Afib comorbidities RF management (Created page with "__NOTOC__ {| class="infobox" style="float:right;" |- | 30px|link=Atrial fibrillation resident survival guide|| || | '''Resident''' '''Survival''' '''Guide''' |} {{Atrial fibrillation}} {{CMG}}; {{AE}} {{SemRikken}}")
17:27, 17 November 2024 Omid Afkhami-Ardakani talk contribs created page Accrufer (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami Ardakani |genericName=Ferric Maltol |aOrAn=an |drugClass=Oral Iron Replacement Therapy |indicationType=treatment |indication=iron deficiency in adults. |adverseReactions=Flatulence, diarrhea, constipation, discolored stools, abdominal pain, nausea, vomiting, and abdominal discomfort or bloating. |fdaLIADAdult=The recommended dosage is 30 mg orally twice daily, taken 1 hour before or 2 hours after a meal. |contraindicati...")
20:12, 2 November 2024 Omid Afkhami-Ardakani talk contribs created page Recarbrio (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami Ardakani |genericName=Imipenem, Cilastatin, and Relebactam |aOrAn=an |drugClass=Antibacterial Combination |indicationType=treatment |indication=Complicated Urinary Tract Infections (cUTI), Complicated Intra-Abdominal Infections (cIAI), and Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia (HABP/VABP) in patients 18 years and older. |adverseReactions=Nausea, Diarrhea, Headache, Fever, an...")

Main public logs

Navigation menu

Search